Product Intro

Cinacalcet HCl is a specific drug for controlling hyperparathyroidism and inhibiting parathyroid hormone PTH. Cinacalcet HCl represents a new type of compound used to treat hyperthyroidism. It is a calcium mimic agent that reduces the synthesis and secretion of parathyroid hormone (PTH) by increasing the sensitivity of parathyroid calcium sensitive receptor (car) to extracellular calcium ions. Cinacalcet HCl, as a therapeutic agent for secondary hyperparathyroidism, has potential advantages because it inhibits PTH secretion by simulating the effect of extracellular calcium ions. Even in the case of hyperphosphatemia, it will not have the risk of hypercalcemia and / or hyperphosphatemia.

Function

It can improve the disorder of bone metabolism in uremia and delay the progression of vascular and valve calcification in dialysis patients. However, long-term use of sinakase will also bring side effects such as nausea and vomiting, hypocalcemia and excessive inhibition of parathyroid hormone (PTH). Sinakasai is characterized by not only reducing the whole serum PTH level, but also reducing the levels of serum calcium, serum phosphorus and the product of serum calcium and phosphorus. It can inhibit the occurrence and progression of cardiovascular disease caused by ectopic calcification.

Application

It is effective for patients with secondary hyperparathyroidism undergoing dialysis due to chronic kidney disease, and has the characteristics of good safety, tolerance and convenience. It has been widely used in clinic.